Pharmacological concentrations of lipid emulsions inhibit interleukin‐2‐dependent lymphocyte responses in vitro
- 1 January 1990
- journal article
- research article
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 14 (1) , 12-17
- https://doi.org/10.1177/014860719001400112
Abstract
Most immunological functions are accomplished by means of interactions between mediator molecules (cytokines or lymphokines) and their specific receptors on the lymphocyte surface. One particular lymphokine, Interleukin‐2 (IL‐2) is central to the generation of most immune responses including those with antitumor activity. Prompted by two clinical trials which have suggested distinct but apparently opposite effects of lipid emulsions on the production of and lymphocyte responses to IL‐2 we have examined the effects of pharmacological concentrations of three lipid emulsions currently in clinical use on IL‐2 related interactions in vitro. Mitogen‐stimulated and IL‐2 activated human lymphocyte proliferation were both inhibited in a dose‐dependent manner in the presence of all three lipid emulsions although the effects were less marked with the solution in which 50% of the calories are present as medium‐chain triglycerides (MCT) rather than long‐chain triglycerides (LCT). Similarly the LCT, but less so the MCT‐containing solutions inhibited the generation of cytotoxic lymphokine‐activated killer cells. These solutions did not inhibit the proliferation of cell lines which are not growth‐factor dependent but did inhibit the growth of an IL‐2‐dependent cell line. We conclude that lipid emulsions can upset IL‐2‐dependent lymphocyte responses. These observations may lead to parenteral feeding regimens which are less immunocompromising for the tumor‐bearing patient.Keywords
This publication has 5 references indexed in Scilit:
- CLINICAL AND IMMUNOLOGICAL EFFECTS OF RECOMBINANT INTERLEUKIN-2 GIVEN BY REPETITIVE WEEKLY CYCLES TO PATIENTS WITH CANCER1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver.The Journal of Immunology, 1985
- A PROSPECTIVE, RANDOMIZED STUDY OF ADJUVANT PARENTERAL-NUTRITION IN THE TREATMENT OF SARCOMAS - RESULTS OF METABOLIC AND SURVIVAL STUDIES1984
- Role of Natural Killer Cells in the Destruction of Circulating Tumor Emboli23JNCI Journal of the National Cancer Institute, 1980